NYSE : PEN

Penumbra, Inc.

$323.21 USD

-$1.01 (-0.31%)

Volume
214.89K
Average Volume
434.93K
Market Capitalization
$12.73B
P/E Ratio
79.02
Dividend Yield
0.00%
Price Target
$347.00
Year High
$362.41
Year Low
$221.26
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$5.75
Company Overview

NYSE

Adam Elsesser

Medical - Devices

Healthcare

PEN

4700

US

USD

https://www.penumbrainc.com

510 748 3200

70975L107

0001321732

Liquidity Metrics

0.14

5.75

3.86

0.88

0.00

Sales & Valuation

$1.4B

8.46

8.30

58.97

5.49

Profitability

$4.52

$177.69M

10.67%

13.54%

11.09%

8.13%

P/E Metrics

79.02

11.64

11.64

Analyst Price Target & Rating

$347.00

$374.00

$320.00

Neutral

3/5

22 Analysts

-6.86%

Financial Health Scores

19.26

5/9

$1.11B

$1.97B

$443.96M

$205.13M

Key Metrics (TTM)

$12.78B

8.49

57.49

5.75

11.09%

8.40%

1.26%

1.69%

$59.82

346 days

Company Executives
Name Title
Lambert Shiu Chief Accounting Officer
Johanna Roberts Executive Vice President, General Counsel & Secretary
Maggie S. Yuen Chief Financial Officer
Shruthi Narayan President
Pankaj Tiwari Executive Vice President & Chief Information Officer
Ben Sorci Executive Vice President of Operations
Ben Tompkins Executive Vice President of Development & Compliance
Adam Elsesser Co-Founder, Chairman & Chief Executive Officer
Jee Hamlyn-Harris Investor Relations Officer
Arani Bose Co-Founder & Director
Poll Results

No votes yet today — be the first to share your view!

About Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and ot ... her components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

2026-07-30 16:05:00

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

Bank of Nova Scotia Acquires 210,402 Shares of Penumbra, Inc. $PEN

2026-07-25 04:05:38

Bank of Nova Scotia boosted its stake in Penumbra, Inc. (NYSE: PEN) by 14,837.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 211,820 shares of the company's stock after purchasing an additional 210,402 shares during the quarter. Bank

California Public Employees Retirement System Increases Position in Penumbra, Inc. $PEN

2026-07-23 03:41:46

California Public Employees Retirement System lifted its stake in shares of Penumbra, Inc. (NYSE: PEN) by 25.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,421 shares of the company's stock after purchasing an additional 12,108 shares during

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

2026-07-22 15:00:00

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care PR Newswire ALAMEDA, Cal

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

2026-07-22 14:35:00

First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates ALAMEDA, Calif., July 22, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO).

Penumbra, Inc. $PEN Shares Sold by Bank of New York Mellon Corp

2026-07-22 03:40:40

Bank of New York Mellon Corp decreased its stake in shares of Penumbra, Inc. (NYSE: PEN) by 0.9% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 246,527 shares of the company's stock after selling 2,129 shares during the

3 Medical Device Stocks Giving Investors a Different Healthcare Play

2026-07-20 09:40:05

When investors think of the health care sector, most imagine the stability of pharmaceutical giants or the high-risk/high-reward profile of up-and-coming clinical stage drug developers. Medical device companies operate within a unique ecosystem and are often easy to overlook.

IQV vs. PEN: Which Stock Is the Better Value Option?

2026-07-14 12:40:26

Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

Frequently Asked Questions

What is the current Penumbra, Inc. (PEN) stock price?

Penumbra, Inc.(NYSE:PEN) stock price is $323.21 in the last trading session. During the trading session, PEN stock reached the peak price of $362.41 while $221.26 was the lowest point it dropped to. The percentage change in PEN stock occurred in the recent session was --0.31% while the dollar amount for the price change in PEN stock was -$1.01.

PEN's industry and sector of operation?

The NYSE listed PEN is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of PEN?

Lambert Shiu | Chief Accounting Officer
Johanna Roberts | Executive Vice President, General Counsel & Secretary
Maggie S. Yuen | Chief Financial Officer
Shruthi Narayan | President
Pankaj Tiwari | Executive Vice President & Chief Information Officer

How many employees does PEN have?

Number of PEN employees currently stands at 4700. PEN operates from One Penumbra Place, Alameda, CA 94502, US.

Link for PEN official website?

Official Website of PEN is: https://www.penumbrainc.com

How do I contact PEN?

PEN could be contacted at phone #510 748 3200 and can also be accessed through its website. PEN operates from One Penumbra Place, Alameda, CA 94502, US.

How many shares of PEN are traded daily?

The average number of PEN shares traded daily for last 3 months was 434.93K.

What is the market cap of PEN currently?

The market value of PEN currently stands at $12.73B with its latest stock price at $323.21